hexamethylene bisacetamide has been researched along with Carcinoma in 3 studies
N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The differentiation agent hexamethylene bisacetamide (HMBA) increased expression of transforming growth factor beta 1 (TGF beta 1) mRNA in HT29 colon carcinoma cells." | 7.68 | Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide. ( Coffey, RJ; Friedman, E; Rifkin, J; Schroy, P; Winawer, S, 1990) |
| "The role of transforming growth factor beta 1 (TGF-beta 1) in enterocytic differentiation was examined by treating two undifferentiated HT29 colon carcinoma sublines, U4 and U9, with hexamethylene bisacetamide to up-regulate their level of TGF-beta 1 mRNA expression." | 3.68 | Two roles for transforming growth factor beta 1 in colon enterocytic cell differentiation. ( Friedman, E; Hafez, MM; Hsu, S; Winawer, S; Yan, Z, 1992) |
| "The differentiation agent hexamethylene bisacetamide (HMBA) increased expression of transforming growth factor beta 1 (TGF beta 1) mRNA in HT29 colon carcinoma cells." | 3.68 | Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide. ( Coffey, RJ; Friedman, E; Rifkin, J; Schroy, P; Winawer, S, 1990) |
| "Murine erythroleukemia cells developed for resistance to SAHA are cross-resistant to trichostatin A, a known deacetylase inhibitor and differentiation inducer, but are not cross-resistant to HMBA." | 1.30 | A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. ( Breslow, R; Emiliani, S; Marks, PA; Richon, VM; Rifkind, RA; Verdin, E; Webb, Y, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Richon, VM | 1 |
| Emiliani, S | 1 |
| Verdin, E | 1 |
| Webb, Y | 1 |
| Breslow, R | 1 |
| Rifkind, RA | 1 |
| Marks, PA | 1 |
| Hafez, MM | 1 |
| Hsu, S | 1 |
| Yan, Z | 1 |
| Winawer, S | 2 |
| Friedman, E | 2 |
| Schroy, P | 1 |
| Rifkin, J | 1 |
| Coffey, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900] | Phase 1 | 6 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for hexamethylene bisacetamide and Carcinoma
| Article | Year |
|---|---|
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.
Topics: Acetamides; Animals; Carcinoma; Cell Differentiation; Cell Line, Transformed; Cell Transformation, N | 1998 |
Two roles for transforming growth factor beta 1 in colon enterocytic cell differentiation.
Topics: Acetamides; Carcinoembryonic Antigen; Carcinoma; Cell Adhesion; Cell Differentiation; Colon; Colonic | 1992 |
Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide.
Topics: Acetamides; Biomarkers, Tumor; Carcinoma; Cell Differentiation; Colonic Neoplasms; Humans; RNA, Mess | 1990 |